Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment.
We describe a case of recurring Candida glabrata infection in a 68-year-old African-American female on caspofungin therapy. The initial isolate was susceptible, but isolates recovered during following relapses were not. All isolates were clonal, and high-MIC strains contained a mutation in the highly conserved hot spot 1 region of Fks1p.
Cleary
John D
JD
Mycotic Research Center, University of Mississippi Schools of Pharmacy and Medicine, Jackson, Mississippi 39216, USA. Jcleary@medicine.umsmed.edu
Garcia-Effron
Guillermo
G
Chapman
Stanley W
SW
Perlin
David S
DS
D000368:Aged; D000935:Antifungal Agents / Q000494:pharmacology* / Q000627:therapeutic use; D041221:Candida glabrata / Q000187:drug effects*; D002177:Candidiasis / Q000188:drug therapy / Q000382:microbiology; D000077336:Caspofungin; D025141:Drug Resistance, Fungal / Q000235:genetics; D054714:Echinocandins / Q000494:pharmacology* / Q000627:therapeutic use; D017809:Fatal Outcome; D005260:Female; D005656:Fungal Proteins / Q000235:genetics; D016469:Fungemia / Q000188:drug therapy* / Q000382:microbiology; D005964:Glucosyltransferases / Q000235:genetics*; D006801:Humans; D055666:Lipopeptides; D008565:Membrane Proteins / Q000235:genetics*; D008826:Microbial Sensitivity Tests; D009154:Mutation
D000935:Antifungal Agents; D054714:Echinocandins; D005656:Fungal Proteins; D055666:Lipopeptides; D008565:Membrane Proteins; D005964:Glucosyltransferases; D000077336:Caspofungin